drugset
drugset / Trial / NCT04892641

Phase 1 Study of Epetraborole Tablets

NCT04892641 ↗

Phase 1 Completed 51 enrolled AN2 Therapeutics, Inc
RandomizedSequentialQuadruple-blindOther

Summary

This is a Phase 1b double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and food effect of epetraborole tablets administered to healthy adult subjects for up to 28 days.

Timeline

Start
2021-06-10
Primary completion
2022-02-26
Completion
2022-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Epetraborole Small molecule 250 mg Oral
Subject Epetraborole Small molecule 500 mg Oral
Subject Epetraborole Small molecule 750 mg Oral
Subject Epetraborole Small molecule 1000 mg Oral

Indications

No indication recorded.